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Abstract 
Background: Immunization with neural derived peptides (INDP) as well as scar removal—separately—have 
shown to induce morphological and functional improvement after spinal cord injury (SCI). In the present study, we 
compared the effect of INDP alone versus INDP with scar removal on motor recovery, regeneration‑associated and 
cytokine gene expression, and axonal regeneration after chronic SCI. Scar removal was conducted through a single 
incision with a double‑bladed scalpel along the stump, and scar renewal was halted by adding α,α′‑dipyridyl.
Results: During the chronic injury stage, two experiments were undertaken. The first experiment was aimed at testing 
the therapeutic effect of INDP combined with scar removal. Sixty days after therapeutic intervention, the expression of 
genes encoding for TNFα, IFNγ, IL4, TGFβ, BDNF, IGF1, and GAP43 was evaluated at the site of injury. Tyrosine hydroxylase 
and 5‑hydroxytryptamine positive fibers were also studied. Locomotor evaluations showed a significant recovery in the 
group treated with scar removal + INDP. Moreover; this group presented a significant increase in IL4, TGFβ, BDNF, IGF1, 
and GAP43 expression, but a decrease of TNFα and IFNγ. Also, the spinal cord of animals receiving both treatments pre‑
sented a significant increase of serotonergic and catecholaminergic fibers as compared to other the groups. The second 
experiment compared the results of the combined approach versus INDP alone. Rats receiving INDP likewise showed 
improved motor recovery, although on a lesser scale than those who received the combined treatment. An increase in 
inflammation and regeneration‑associated gene expression, as well as in the percentage of serotonergic and catechola‑
minergic fibers was observed in INDP‑treated rats to a lesser degree than those in the combined therapy group.
Conclusions: These findings suggest that INDP, both alone and in combination with scar removal, could modify the 
non‑permissive microenvironment prevailing at the chronic phase of SCI, providing the opportunity of improving 
motor recovery.
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Background
After SCI, numerous anatomical and physiological self-
destructing mechanisms are triggered. These events 
induce a discontinuity in the spinal cord (SC) paren-
chyma [1–3]. One of these events is the inflammatory 
response, a phenomenon that could exert beneficial 
effects after SCI [4]. Recent studies have demonstrated 
that modulation of the immune response confers protec-
tive and reparative effects after central nervous system 
(CNS) injury [5, 6]. This phenomenon—termed protec-
tive autoimmunity (PA), is a novel therapeutic paradigm 
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that has been used to promote neuroprotection and neu-
ral restoration.
This particular strategy is achieved by immunizing 
with neural-derived peptides (INDP) such as A91, a pep-
tide derived from the 87-99 immunogenic sequence of 
amino acids that give structure to the myelin basic pro-
tein (MBP). Activation of T-Lymphocytes by A91-pep-
tide induces an anti-inflammatory Th2 response that 
allows microglia to differentiate into an M2 phenotype. 
The resulting microenvironment after immunization is 
characterized by a low production of free radicals and 
several neuroprotective mechanisms [7, 8]. The thera-
peutic effect of PA has already been reported when INDP 
is performed immediately after SCI; however, there is no 
published data describing the effect of this strategy when 
administered during the chronic phase of injury.
In order to achieve the beneficial effects of this therapy, 
it is important to consider the prevailing environment at 
chronic stages of injury. The glial scar formation—that 
acts as a physical barrier—is one of the main obstacles to 
allow the action of this therapeutic intervention. Another 
important feature of the chronic phase of injury is the 
lack of molecules that were activated—either as protec-
tive or restorative promoters—throughout the acute 
phase of injury [4]. Chronic SCI is considered a period 
of stability and low activity at the site of injury, followed 
by a progressive decline in the neurological function of 
injured individuals [9].
Under these conditions, scar removal could help 
to allow regenerating axons to grow across the site of 
injury, and re-establish the characteristic conditions of 
the acute phase of the lesion (e.g. neurotrophic factors 
and cytokine release). The renewed microenvironment 
could provide the conditions for PA to exert its benefi-
cial actions; especially those related to neural restoration 
[10]. Taking this approach into consideration, our group 
developed a reproducible surgical procedure that allows 
the elimination of the glial scar without causing signifi-
cant collateral neurological damage. In the first step of 
this work, we explored whether INDP in combination 
with scar removal provides an appropriate microen-
vironment to promote neural restoration. During this 
preliminary study, we evaluated locomotor recovery, 
regeneration-associated and cytokine gene expression, 
as well as the number of regenerating axons, in a model 
of chronic SCI. The second step compared whether the 
results of the combined therapy provided better results 
when compared to INDP alone.
Methods
Experimental design
Sample size for this experiment was calculated using 
an alpha of 0.05 and beta of 0.20. Experiments were 
performed 60  days after SCI, with subsequent analy-
ses carried out over the two following months. The first 
experiment consisted of 27 SCI rats randomly distributed 
in the following three groups (GraphPad QuickCalcs: 
http://www.graphpad.com/quickcalcs/): (1) sham oper-
ated rats (SC is exposed but scar tissue is not removed) 
immunized with PBS (n = 9); (2) rats with scar removal 
alone (n = 9); (3) rats with scar removal + INDP (n = 9). 
The second experiment was composed of 24 SCI rats 
randomly allocated into three groups: (1) sham oper-
ated rats immunized with PBS (n = 8); (2) rats with scar 
removal + INDP (n = 8); (3) rats with INDP but without 
scar removal (n = 8). Basal statistical analysis of weight, 
age, and Basso, Beattie and Bresnahan (BBB) score 
yielded no statistical significance between experimental 
groups.
Once animals were allocated into the groups, a blinded 
surgeon performed the corresponding intervention. 
After intervention, motor recovery was weekly evalu-
ated for a period of 60 days. At the end of each experi-
ment, rats were euthanized, and the SC was analyzed for 
the expression of inflammation-related genes. Addition-
ally, we determined the expression of some regeneration-
associated genes and the number of regenerating axons.
Ethics statement
All animals were handled according to NIH guidelines for 
the management of laboratory animals. All procedures 
were performed in accordance to the National Institutes 
of Health Guide for the care and use of laboratory ani-
mals, and the Mexican Official Norm on the Principles of 
Laboratory Animal Care (NOM 062-ZOO-1999).
Spinal cord injury
Adult female Sprague–Dawley rats weighing between 230 
and 250 g were subjected to moderate SC contusion. Ani-
mals were anesthetized by an intramuscular injection of a 
mixture of ketamine (50 mg/kg, Probiomed, Mexico City, 
Mexico) and xylazine (10  mg/kg, Fort Dodge Laborato-
ries, Fort Dodge, Iowa). Skin was opened in layers and 
a laminectomy was performed at the T9 level of the SC. 
Subsequently, a 10 g rod was dropped onto the SC from 
a height of 25 mm using the NYU impactor (NYU, New 
York). Functional recovery of all groups was assessed by 
the BBB locomotor scale [11, 12].
Postoperative care
After SCI; animals were housed with food and water 
ad  libitum, and received manual bladder voiding, three 
times a day for 2  weeks. To avoid infection, Enrofloxa-
cin (Marvel, Mexico City, Mexico) was diluted into their 
drinking water at an approximate dose of 64 mg/kg/day 
for 1 week. Animals were carefully monitored for signs of 
Page 3 of 13Rodríguez‑Barrera et al. BMC Neurosci  (2017) 18:7 
infection, dehydration or auto mutilation with appropri-
ate veterinary assistance as needed.
Antigen (A91 peptide)
The A91 peptide was derived from the encephalito-
genic sequence—amino acids 87-99—of the myelin 
basic protein (MBP). A non-encephalitogenic analogue 
was obtained by replacing lysine residue for alanine at 
position 91. The modified peptide was purchased from 
Invitrogen Life Technologies (San Diego CA, USA). 
Reverse-Phase HPLC confirmed the purity of the A91 
peptide (>95%).
Active immunization
Rats were immunized subcutaneously at the base of 
the tail with 200 μg of A91 in phosphate buffered saline 
(PBS), emulsified in an equal volume of complete Fre-
und’s adjuvant (CFA) containing 0.5  mg/ml Mycobacte-
rium tuberculosis (Sigma, St. Louis MO). Immunization 
was performed within a 60 min frame after injury.
Removal and inhibition of scar formation
Two months after SCI, animals were anesthetized again 
as previously described. Thirty minutes after anes-
thetic induction, a longitudinal incision was performed 
until the fibrous tissue was identified. Using surgi-
cal microscopy, fibrosis was removed until meninges 
were clearly visible. A second longitudinal incision was 
then performed, and the meninges were referenced to 
the bordering muscles with a 9-0 suture. The exposed 
area was cleaned with saline solution, and necrotic 
tissue was eliminated. The scar from each stump was 
then removed through a single incision with a double-
bladed scalpel. The surgeon was trained to perform 
reproducible procedures and was blinded to the group 
of animals.
This method is helpful to successfully remove the glial 
scar but also causes a slight lesion that allows a renewed 
production of growth factors, and thus the formation of a 
favorable microenvironment. It is important to mention 
that this type of lesion does not generate any additional 
neurological deficit. Once the scar was removed, its 
renewal was halted by adding α,α′-dipyridyl (DPY). DPY 
was injected directly –six times– into each stump of the 
SC by using a Hamilton syringe. Each injection deposited 
2 µL volume of DPY (16 nmol) diluted in PBS.
Functional recovery evaluation
Motor recovery was assessed by the BBB open-field loco-
motor scale method. Animals were evaluated weekly 
throughout 8  weeks by three observers blinded to the 
treatment. The average of the three scores was used.
Semiquantitative gene expression
Gene expression of Tumor necrosis factor alpha 
(TNFα), Interferon gamma (INFγ), Interleukin 4 (IL-
4), Transforming growth factor-beta 3 (TGFβ3), Brain 
derived neurotrophic factor (BDNF), Insulin-like 
growth factor-1 (IGF-1), Growth associated protein 43 
(GAP-43), β-Actin, and HPRT [hypoxanthine phospho-
ribosyl transferase (housekeeping gene)] was determined 
by qRT-PCR, 120  days after injury. Total RNA (RNAt) 
was isolated from a 1.0  cm-long sample taken from the 
injury site of the spinal cord (0.5 cm caudal/0.5 cm ros-
tral) using the Trizol method (Invitrogen, Carlsbad, CA, 
USA). Then, cDNA was synthesized from 2  µg of total 
RNA using the Superscript II transcriptase enzyme and 
Oligo dT (Invitrogen, Carlsbad, CA, USA). Primers were 
designed by Custom Primers OligoPerfect™ designer 
(http://tools.invitrogen.com) and confirmed by Primer 
analysis software [Oligo] (Molecular Biology Insights, 
Inc). The forward (F) and reverse (R) primers, amplicon 
size, and GeneBank entry numbers are listed in Table 1.
Reactions were performed with the FastStart Essential 
DNA Green Master kit (Roche, Diagnostics, Indianapo-
lis, USA). The amplification was detected with a Light 
Cycler 96 instrument (Roche Diagnostics, Indianapolis, 
USA). All groups were compared to PBS-immunized ani-
mals. Relative concentrations were calculated by the Cq 
method (i.e., the cycle number in which the exponential 
amplification of the template begins) running the sec-
ond derivative. The average value of each sample was 
obtained. Expression value from each analyzed gene was 
Table 1 Real-time PCR primers
Gene GenBank Primer sequence Product 
length (bp)
TNFα MN_012675 F tgacccccattactctgacc
R ttcagcgtctcgtgtgtttc
152
INFϒ MN_138880 F agcatggatgctatggaagg
R ctgatggcctggttgtcttt
146
IL4 MN_201270 F gaaaaagggactccatgcac
R tcttcaagcacggaggtaca
145
TGFβ3 NM_013174.1 F cccaacccccagctccaagcg
R cagccactctgcggtggctc
132
BDNF MN_001270630 F tggcctaacaatgtttgcag
R cagctccacttagcctccac
114
IGF1 MN_001082477 F cttaggggctagcctcaggt
R gttccgatgttttgcaggtt
158
GAP43 NM_017195.3 F ctaaggaaagtgcccgacag
R gcaggagagacagggttcag
117
β‑ACTIN NM_007393 F agggccaaccgtgaaaag
R gtggtacgaccagaggcatac
110
HPRT NM_012583.2 F aagcttgctggtgaaaagga
R caaagcctaaaagacagcgg
192
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compared to that of the housekeeping gene by assigning 
a value equal to one to the latter for the normalization of 
the expression.
Immunohistochemistry
Eight weeks after the therapeutic intervention, animals 
were euthanized with an overdose of sodium pento-
barbital (80  mg/kg) and intracardiac perfusion with 4% 
paraformaldehyde. The affected portions of the SC were 
fixed overnight and then transferred to 30% sucrose for 
cryoprotection. Samples were embedded in Tissue-Tek 
(Miles Elkhart, IN, USA), and longitudinal frozen sec-
tions (40 μm thick) were performed. Immunohistochemi-
cal staining was carried out in order to count the amount 
of positive TH and 5-TH fibers. Tissues were incubated 
in 0.03% hydrogen peroxide to quench endogenous per-
oxidase activity. Subsequently, the tissue was incubated 
overnight with the following primary antibodies: mono-
clonal goat antibody against TH (1:2000; Chemicon), or 
polyclonal rabbit antibody against 5-HT (1:2000; Sigma-
Aldrich). Following rinsing with PBS, samples were 
incubated for at least 2 h with donkey IgG anti-goat IgG 
(1:500; Chemicon) and Sheep IgG anti rabbit IgG (1:500; 
Abcam) secondary biotinylated antibodies. To visualize 
positive fibers, samples were incubated 5 min with Vector 
DAB kit (Vector laboratories, CA, USA). Then, samples 
were evaluated and analyzed by a blinded observer that 
counted individual fibers using a 20× objective (Olympus 
DP72, Japan). The amount of regenerating axons at the 
epicenter and 1 mm caudal to the lesion was assessed.
Statistical analysis
Data is displayed as mean ± standard deviation (SD), and 
statistical significance was established when p  ≤  0.05. 
GraphPad Prism 5.0 (GraphPad Software, Inc. La Jolla, 
CA, USA) was employed in statistical analysis. Data from 
the assessment of functional recovery was analyzed using 
Kruskal–Wallis test, ANOVA with Bonferroni’s post hoc 
test for repeated measures, and Mann–Whitney U or 
Fisher’s exact probability tests. Gene expression results, 
as well as percentage of serotoninergic and catecholamin-
ergic axon fibers, were analyzed by One-way ANOVA 
followed by Tukey–Kramer post hoc test.
Results
Immunization with neural derived peptides plus scar 
removal improved motor recovery after chronic SCI
Evaluation of motor recovery before therapeutic inter-
vention demonstrated that the BBB score was similar in 
the 3 groups (scar removal: 6.00 ±  1.031; PBS-immuni-
zation: 6.16 ±  0.25; scar removal +  INDP: 6.33 ±  1.47; 
mean ± standard deviation (SD); Fig. 1a). Sixty days after 
intervention (120 days after SCI), rats submitted to scar 
removal + INDP showed a significant increase in motor 
recovery (8.11  ±  1.69; p  <  0.05, ANOVA for repeated 
measures with Bonferroni’s post hoc test; Fig. 1b) when 
compared to those with scar removal alone (6.22 ± 1.85) 
or PBS-immunization (6.38 ±  0.48). Noteworthy, 55.5% 
of animals subjected to scar removal  +  INDP showed 
a locomotor improvement equal or above 9 in the BBB 
rating score (plantar paw placement with weight sup-
port instance). This percentage of animals was signifi-
cantly different (p < 0.05; Fisher’s exact probability test) 
as compared to scar removal (0%) or PBS-immunized 
(0%) groups. When motor function (from each group) 
was compared before and after therapeutic interven-
tion, we only found a significant difference in the scar 
removal + INDP group (p < 0.05; Wilcoxon test; Fig. 1c).
Immunization with neural derived peptides 
plus scar removal generates a microenvironment 
where anti‑inflammatory cytokine 
and regeneration‑associated gene expression prevails
In order to confirm that scar removal  +  INDP indeed 
provides a permissive microenvironment for neural 
regeneration, inflammatory (TNFα and IFNγ) and anti-
inflammatory (IL4, TGFβ), as well as regeneration-asso-
ciated gene expression, was evaluated at the site of injury.
Figure  2a shows that relative expression of TNFα was 
significantly reduced in rats with scar removal +  INDP 
(0.02  ±  0.58) as compared to the one observed in the 
group of PBS-immunization (1.00  ±  0.62) or scar 
removal only (0.64 ± 0.84; p < 0.05, Kruskal–Wallis fol-
lowed by Man-Whitney U test). The expression of the 
gene encoding for IFNγ was significantly increased in 
animals with scar removal alone (12.04 ± 0.55; p < 0.05 
One-way ANOVA followed by Tukey test; Fig.  2b), but 
reduced in rats with scar removal + INDP (0.82 ± 0.83).
On the other hand, scar removal  +  INDP induced 
a significant increase of the genes encoding for IL4 
(12.0 ± 0.34) and TGFβ (58.77 ± 0.59) when compared to 
PBS-immunized (1.00 ±  2.06; 1.00 ±  0.19, respectively) 
and scar removal groups (0.004  ±  0.26; 4.56  ±  0.09 
respectively) (Fig.  2c, d; One-way ANOVA followed by 
Tukey–Kramer post hoc analysis).
Regeneration-associated genes (BDNF, IGF1, and 
GAP43) were also examined. The relative expression of 
BDNF (2.80  ±  1.71, p  <  0.05 Kruskal–Wallis followed 
by Mann–Whitney U test), IGF1 (93.60 ± 0.74; p < 0.05 
One-way ANOVA followed by Tukey–Kramer test), 
and GAP43 (123.22 ±  0.28; One-way ANOVA followed 
by Tukey test) was significantly increased in the group 
of rats with scar removal  +  INDP, when compared to 
PBS-immunized (1.00 ±  1.18; 1.00 ±  0.10; 1.00 ±  1.55, 
respectively) and scar removal (0.12 ± 0.35; 0.87 ± 0.51; 
23.48 ± 0.33, respectively) groups (see Fig. 3a–c).
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Immunization with neural derived peptides plus scar 
removal promotes axonal regeneration
To determine if the permissive-anti-inflammatory micro-
environment generated by scar removal + INDP had any 
positive effect on axonal regeneration; we assessed the 
percentage -obtained from the total number of fibers 
observed in sham-operated rats- of immunoreactive (IR) 
fibers to serotonin (5-HT) and tyrosine hydroxylase (TH) 
in the SC of studied animals.
Figure  4a shows a significant increase of 5-HT-IR 
fibers in the caudal stump of rats subjected to scar 
removal  +  INDP. In this group, fiber percentage was 
significantly higher (46.70 ± 7.50; mean ± SD) than the 
one observed in PBS-immunized (23.18  ±  3.60) and 
scar removal (16.21  ±  2.0; p  <  0.05, One-way ANOVA 
followed by Tukey–Kramer test) groups. Furthermore, 
scar removal  +  INDP induced a significant increase 
in the percentage of TH-IR axons in the caudal stump 
(39.0  ±  3.20; mean  ±  SD, p  <  0.05, One-way ANOVA 
followed by Tukey–Kramer test; Fig.  4b) as compared 
to PBS-immunized (17.06  ±  2.97) or scar removed 
(15.49 ± 1.95) groups.
Immunization with neural derived peptides alone also 
improves motor recovery in chronic SCI
The second experiment was aimed at determining 
whether performing a slight injury was necessary in 
order to activate the beneficial effect of PA, or whether 
INDP alone was sufficient to promote neural restoration 
in the chronic phase of SCI. The study population for 
this experiment consisted of twenty-four rats subjected 
to SCI. Two months after injury, rats were allocated into 
three groups as follows: (1) sham operated rats (SCI with 
surgical intervention but no scar removal) immunized 
with PBS (n  =  8); (2) rats with scar removal  +  INDP 
(n  =  8); (3) rats with INDP plus sham operation with 
no scar removal (n =  8). Rats treated with INDP alone 
showed improved locomotion recovery, although the 
effect was not as marked as the one observed in the com-
bined INDP + scar removal group (Fig. 5).
Baseline BBB scores calculated 60 days after SCI were 
similar among all groups (5.8 ± 0.1; Fig. 5a). At the end 
of the follow-up period after intervention, animals with 
scar removal  +  INDP presented higher motor recov-
ery (9.0  ±  0.3; Fig.  5b) than those with INDP alone 
(7.8  ±  0.8) or those in the PBS-immunized group 
(5.75 ± 0.2). In the same way, the group receiving com-
bined scar removal +  INDP presented the highest per-
centage of rats with BBB scores equal to or above 9 points 
(62.5%) when compared to those with INDP alone (50%) 
Fig. 1 Locomotor recovery of rats before and after intervention. a 
There was not a significant difference among groups before interven‑
tion (p > 0.05; Kruskal–Wallis test. Mean ± SD is depicted for each 
group). b After intervention, a significantly better motor recovery 
was observed in the SR + INDP group. *p < 0.05, ANOVA for repeated 
measures with Bonferroni’s post hoc test. Each point represents the 
mean ± SD of 9 rats. c Comparison of the BBB score observed before 
(B) or after (P) therapeutic intervention. Rats subjected to SR + INDP 
presented a significant improvement after intervention. *p < 0.05 
versus SR + INDP‑B, Mann–Whitney U test. Mean ± SD is depicted for 
each group. PBS-I PBS‑immunization, SR scar removal, SR + INDP scar 
removal + immunization with neural derived peptides
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and PBS-immunization (0%). The difference between the 
combined INDP  +  scar removal group and the INDP 
alone group was statistically significant (p  <  0.05; Fish-
er’s exact probability test), as well as between these two 
groups and the PBS-immunized group (p < 0.05). Com-
parison of motor function before and after therapeutic 
intervention showed that both scar removal  +  INDP 
and INDP alone groups presented significant recovery 
(p < 0.05; Wilcoxon test; Fig. 5c).
The microenvironment generated by INDP alone is also 
permissive, although to a lesser degree than the one 
induced by scar removal + INDP
IFNγ and TNFα gene expression was significantly 
reduced in INDP treated rats when compared to PBS-
immunized ones (0.18  ±  2 and 0.21  ±  2 respectively; 
p  <  0.05, One-way ANOVA followed by Tukey–Kramer 
post hoc test). In a similar manner, there was a reduc-
tion in the expression of these genes in animals with scar 
removal  +  INDP (0.21  ±  3 and 0.17  ±  2 respectively; 
Fig. 6a, b, p < 0.05 vs. PBS-immunized group). There was 
no significant difference between INDP alone and scar 
removal + INDP (p > 0.05). IL-4 and TGFβ gene expres-
sion was significantly increased in rats treated only with 
INDP versus PBS-immunized rats (6.6 ± 1 and 32.6 ± 4 
respectively; p  <  0.05, One-way ANOVA followed by 
Tukey–Kramer post hoc test), although results were not 
as high as those observed in the scar removal +  INDP 
group (11.4 ±  2 and 56.8 ±  7 respectively; p  <  0.01 vs. 
PBS-immunized rats and p < 0.05 vs. INDP alone; Fig. 6c, 
d). Expression of regeneration-associated genes was 
significantly increased in rats treated with INDP alone 
(see Fig.  7; BDNF: 1.98  ±  0.3; IGF1: 39.2  ±  8; GAP43: 
65.8  ±  6); however, it was also lower than that of the 
scar removal  +  INDP group (BDNF: 3.2  ±  0.4; IGF1: 
70.9 ± 0.9; GAP43: 105.8 ± 9, p < 0.05 One-way ANOVA 
followed by Tukey test).
Figure  8a shows a significant increase of 5-HT-IR fib-
ers in the caudal stump of rats subjected to INDP alone. 
Fiber percentage in this group was significantly higher 
Fig. 2 Relative expression of inflammation‑related genes at the site of injury. The expression of TNFα (a) and INFγ (b) was significantly reduced in 
rats with scar removal + INDP. This group also presented a significant increase in IL4 (c) and TGFβ (d). *p < 0.05 versus all groups, **p < 0.001 versus 
all groups, ***p = 0.0001 versus all groups, One‑way ANOVA followed by Tukey–Kramer post hoc analysis. Each bar represents the mean ± SD of 4 
rats
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(28.64  ±  4.20; mean  ±  SD) than the one observed in 
PBS-immunized (12.58 ±  2.38) rats (p  <  0.05, One-way 
ANOVA followed by Tukey–Kramer test). Neverthe-
less, the percentage of axons presented by the INDP-
treated group was lower than the one observed in scar 
removal  +  INDP-treated animals (45.61  ±  8.0). There 
was a significant increase in the percentage of TH-IR 
axons in the caudal stump in the combined treatment 
group (43.53  ±  3.1; mean  ±  SD, p  <  0.05, One-way 
ANOVA followed by Tukey–Kramer test; Fig. 8b) when 
compared to INDP (30.39  ±  3.79) or PBS-immunized 
(17.06 ± 2.97) groups.
Discussion
Previous studies have demonstrated that INDP promotes 
neuroprotection after CNS damage [13, 14]. Moreover, 
recent investigations have also shown that this strategy is 
capable of inducing neural restoration [15]. These benefi-
cial effects are observed especially when INDP is admin-
istered immediately after injury. In the present study, we 
explored the effect of this therapy in the chronic phase 
of SCI, a scenario characterized by a marked period of 
stability where protective and restorative promoters are 
no longer present. During this phase, the elements of 
the immune system are also under diminished activity; 
even though, they continue with their remodeling labor 
[4], its grade of activation is low. In order to break with 
this unproductive phase and simultaneously eliminate 
the physical barrier presented by gliosis and collagen 
fibers, we designed our first experiment to include scar 
removal and modulation of the immune response by 
means of INDP. We envisioned that scar removal could 
provide a favorable environment to obtain the beneficial 
effects of INDP. Under the light of this contention, the 
present work had the objective to elucidate the effect of 
this combination treatment in chronic SCI. Collectively, 
our results showed that scar removal  +  INDP, induced 
a significant improvement in motor recovery. This ben-
eficial effect was accompanied by a compelling increase 
in the expression of anti-inflammatory (IL-4 and TGFβ) 
and regeneration-associated genes (BDNF, IGF1, and 
GAP-43). In the same way, this group of rats exhibited a 
better number of regenerating axons. These results could 
be of remarkable significance since they reveal that stabil-
ity and progressive degeneration observed at the chronic 
phase of SCI, may be interrupted and moreover, it could 
be reverted into a suitable microenvironment for neuro-
logical recovery.
Throughout the second experiment, we demonstrated 
that treatment with INDP alone also has the ability to 
revert the state of stability and progressive degeneration 
observed in the chronic phase of injury. However, rats 
who received this therapy did not experience the same 
degree of benefits as those in the scar removal +  INDP 
group.
A number of diverse factors could be responsible for 
the difference observed between these two groups. First 
among these, -as aforementioned- is the establishment 
of a permissive microenvironment for increased INDP 
Fig. 3 Relative expression of regeneration‑associated genes at 
the site of injury. There was a significant increase in the expres‑
sion of BDNF (a), IGF‑1 (b) and GAP‑43 (c) in the group with scar 
removal + INDP. *p < 0.05 versus all groups, **p < 0.05 versus PBS‑I, 
***p < 0.001 versus SR and p < 0.0001 versus PBS‑I, One‑way ANOVA 
followed by Tukey–Kramer post hoc test. Each bar represents the 
mean ± SD of 4 rats
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activity through scar removal. In contrast, the lack of scar 
removal hinders the ability of INDP to exert its benefi-
cial effects, due to a less permissive microenvironment. 
Another possible factor contributing to the lower effect 
observed in rats treated with INDP alone is the physical 
and chemical barrier posed by the scarring itself. In this 
regard, conflicting evidence exists over the importance 
of scar tissue as a barrier for axonal growth. A number 
of reports supporting the role of scar tissue as a barrier 
have shown that its removal facilitates neural restoration 
[16–18]. However, recent studies have also suggested that 
scar tissue is not necessarily an obstacle for regeneration 
and may even be necessary for neural restoration [19]. 
In the present work, we demonstrated that INDP alone 
promotes motor recovery, although this effect is aug-
mented with glial scar removal. Further detailed studies 
evaluating the necessity of scar removal in INDP treat-
ment should be carried out.
In the present study, over 50% of rats treated either 
with scar removal +  INDP or INDP alone presented an 
improvement in locomotion, scoring equal or higher than 
9 in the BBB rating scale (plantar paw placement with 
weight support in stance). Interestingly, these groups 
showed a BBB score of 6 before treatment (60 days after 
SCI). This encouraging effect could only be the result of 
a regenerative process, since, after therapy some animals 
recovered not only the capacity to support their weight, 
but regain the ability to perform plantar stepping (BBB 
score of 10). Since these findings suggested the appear-
ance of a regenerative process as the responsible for gen-
erating the motor improvement, we investigated whether 
the microenvironment generated in each group (scar 
Fig. 4 Percentage of axons observed at the epicenter and caudal stump of SCI rats after therapeutic intervention. The percentage was obtained 
from the total number of axons observed at the same level in sham‑operated rats. Animals treated with scar removal + INDP (SR + INDP) presented 
a significant increase in the total amount of serotoninergic (a) and catecholaminergic (b) fibers. *p < 0.05, versus all groups, One‑way ANOVA fol‑
lowed by Tukey–Kramer post hoc. Each bar represents the mean ± SD of 5 rats. PBS-I PBS immunization, SR scar removal. c, d Microphotographs 
representative of each analyzed therapy group
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removal +INDP and INDP alone) was propitious for 
inducing this favorable outcome. In this way, we found a 
significant amount of IL-4 and TGFβ, which are strongly 
related to neuroprotective and regenerative processes. 
For instance, IL-4 may exert neuroprotective effects by 
regulating the acute and chronic macrophage responses 
[20]. In the same way, this cytokine promotes growth, 
phagocytic activity, and proliferation of microglial cells. 
IL-4 also inhibits the production of nitric oxide (NO) 
and pro-inflammatory cytokines such as TNFα and INFγ 
[21].
On the other hand, IL-4 also provides beneficial 
effects on neural restoration. It has been shown that this 
cytokine is capable of inducing axonal outgrowth in an 
ex  vivo model, as incubation of neuronal cultures with 
IL-4 promoted an enhanced elongation of axons. This 
study demonstrated the recovery of injured neurons by 
activation of neuronal IL-4 receptors, enhancing neuro-
trophin signaling via the AKT and MAPK pathways [22]. 
Moreover, it has been demonstrated that IL-4 increases 
the expression of IGF-1, an important molecule that con-
tributes to neurite outgrowth [23]. Our work showed 
that INDP induced a favorable IL-4 microenvironment; 
thereby, we could expect its beneficial actions at the site 
of injury.
TGFβ could also be supporting restorative mechanisms 
after SCI, since it participates in the regulation of neu-
ron survival and orchestration of repair processes in the 
CNS [24]. TGFβ is a pleiotropic molecule with specific 
key roles in cell differentiation, proliferation, migration, 
extracellular matrix metabolism, and immunosuppres-
sion [24–27]. Evidence suggests that this molecule could 
also play a role in the regulation of adult neurogenesis 
[27].
The increment of IL-4 and TGFβ, as well as the reduc-
tion of TNFα and INFγ, contribute to the induction of 
a permissive microenvironment that is favorable for 
the action of restorative molecules. With this in regard, 
studies in our laboratory have already shown that INDP 
promotes an in  vitro and in  vivo production of neuro-
trophic factors [13, 15]. Interestingly, it has been demon-
strated that the production of this molecules could last 
until chronic stages of SCI [28]. In the present study, we 
observed a significant increase of regeneration-associ-
ated genes such as BDNF, IGF-1, and GAP-43 in rats with 
chronic SCI treated with scar removal + INDP or INDP 
alone. This finding could explain, at least in part, the 
motor recovery observed in both of these groups, with 
animals presenting a significant increase in the expres-
sion of genes encoding for molecules intimately related to 
neural restoration.
Fig. 5 Motor recovery of rats subjected either to scar 
removal + INDP or INDP alone. a There was no significant difference 
among groups before intervention (p > 0.05; Kruskal–Wallis test. 
Mean ± SD is depicted for each group). b After intervention, rats 
treated with SR + INDP or INDP only showed a significant increase 
in motor performance when compared to PBS‑immunized ones. 
*p < 0.01 versus PBS‑I and p < 0.05 versus INDP, **p < 0.05 versus 
PBS‑I. ANOVA for repeated measures with Bonferroni’s post hoc test. 
Each point represents the mean ± SD of 8 rats. c Comparison of the 
BBB score observed before (B) and after (P) therapeutic intervention. 
Rats subjected to combined SR + INDP or INDP alone presented sig‑
nificant improvement after intervention. *p < 0.05. Mann–Whitney U 
test. Mean ± SD is depicted for each group. PBS-I PBS‑immunization, 
INDP immunization with neural derived peptide, SR + INDP scar 
removal + INDP
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BDNF also plays a significant role in neural repair and 
plasticity, as it exerts different effects after trauma to 
the CNS. Some of these effects include neurogenesis, 
axonal sprouting, myelination, and adaptive synaptic 
plasticity [29, 30]. In fact, it is endowed by immediate 
actions that have a direct impact on synaptic transmis-
sion [31]. On the other hand, IGF-1 promotes neurite 
outgrowth of various neuronal populations both in vitro 
and in vivo [32]. Moreover, expression of IGF-1R mRNA 
promotes spinal motor neuron survival and enhances 
neurite outgrowth in sympathetic neurons [31]. The 
increased release of BDNF and IGF-1 by microglia and 
macrophages has been associated with an increased neu-
rogenesis from endogenous neural precursor cells after 
SCI. Moreover, BDNF may be coupled to the induction of 
GAP-43 [33, 34], a common mediator of the regenerative 
effect of BDNF [35]. Interestingly, GAP-43 is essential for 
the neurotrophic functions of BDNF [33], in fact; in mod-
els of cervical axotomy, BDNF injection stimulates GAP-
43 expression, and consequently induces axogenesis and 
repair [36]. These findings could explain the increase of 
GAP-43 observed in the group of rats treated with com-
bined scar removal + INDP and in those receiving INDP 
alone. GAP-43 is involved in translating fundamen-
tal signals for growth cone guidance [37]. Also, several 
studies point to a possible role for GAP-43 in regulating 
neurotransmitter release [33, 38, 39]. GAP-43 is a use-
ful marker, and plays a major role in neurite formation, 
regeneration and neuroplasticity [34]. Altogether, these 
findings support the idea that BDNF, IGF-1, and GAP-43 
strongly contribute to neural restoration. In the present 
investigation, the increase in gene expression encoding 
Fig. 6 Inflammation‑related gene expression in INDP‑treated rats at the site of injury. TNFα (a) and INFγ (b) expression was significantly reduced 
in the scar removal + INDP treatment group and the INDP alone group. Both groups also presented a significant increase in IL4 (c) and TGFβ (d) 
expression. *p < 0.05 versus all groups, **p < 0.05 versus PBS‑I, ***p = 0.001 versus PBS‑I and p < 0.05 versus INDP, One‑way ANOVA followed by 
Tukey–Kramer post hoc analysis. Each bar represents the mean ± SD of 4 rats
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for these molecules was associated to a significant aug-
mentation in the number of descending fibers at the cau-
dal stump of the SC.
Serotonergic (5-HT-positive) and catecholaminergic 
(TH-positive) axons in the SC are descending neuron 
fibers located in the raphe and coeruleus nucleus respec-
tively. SCI produces a decrease in these fibers at caudal 
levels from the site of injury [40, 41]. The microenviron-
ment observed in rats treated with scar removal + INDP 
and in those treated exclusively with INDP was associ-
ated with a significant increase in the number of fibers at 
Fig. 7 Regeneration‑associated genes in INDP‑treated rats at the site 
of injury. There was a significant increase in BDNF (a), IGF‑1 (b) and 
GAP‑43 (c) expression in rats treated with scar removal + INDP and 
those with only INDP. *p < 0.05 versus PBS‑I, **p < 0.01 versus PBS‑I 
and p < 0.05 versus INDP, One‑way ANOVA followed by Tukey–Kramer 
post hoc test. Each bar represents the mean ± SD of 4 rats
Fig. 8 Percentage of axons observed at the epicenter and caudal 
stump of SCI rats after therapeutic intervention. The percentage was 
obtained from the total number of axons found at the same level in 
sham‑operated rats. Animals treated either with scar removal + INDP 
(SR + INDP), or INDP alone presented a significant increase in the 
percentage of serotoninergic (a) and catecholaminergic (b) fibers. 
*p < 0.05, versus PBS‑I, **p < 0.01 versus PBS‑I, and p < 0.05 versus 
INDP. One‑way ANOVA followed by Tukey–Kramer post hoc. Each bar 
represents the mean ± SD of 4 rats. PBS-I PBS immunization, INDP 
immunization with neural derived peptide
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the caudal segment of the SC. This finding supports the 
idea of a permissive microenvironment that promotes the 
formation of new fibers.
Finally, this study also showed an increased expression 
of the gene encoding for INFγ in rats subjected only 
to scar removal. This observation provides evidence 
regarding the modulatory effect exerted by INDP (in the 
case of rats treated either with scar removal + INDP or 
with INDP alone). Furthermore, these results empha-
size that even after minimum injury—scar removal—
there is a significant inflammatory response that could 
be playing an important role in tissue degeneration, 
and also over the lack of functional regeneration. With 
this in regard, there is evidence demonstrating that 
pro-inflammatory stimuli suppress the production of 
neural growth factors [42]. This finding was partially 
supported by our results since animals treated only 
with scar removal, did no present a significant increase 
in the expression of the genes encoding for BDNF or 
IGF-1. Interestingly, scar removal induced a signifi-
cant increase in the expression of the gene encoding 
for GAP-43. However, none of the animals reached the 
score of 9 on the BBB scale. The latter demonstrates, in 
some way, that the microenvironment induced by INDP 
is required to achieve the best conditions as to gain a 
better neurological improvement.
Conclusions
Collectively, our results suggest that both, combined 
therapy consisting of scar removal  +  INDP and INDP 
alone could substantially modify the non-permissive 
microenvironment prevailing at the chronic phase of SCI, 
providing the opportunity to promote a higher motor 
recovery. Of these, combined scar removal + INDP ther-
apy demonstrated greater beneficial effects.
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